Login / Signup

Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA).

Rahul N KhuranaPauline T MerrillSteven YehEric SuhlerMark R BarakatEduardo UchiyamaChristopher Ryan HenryMilan ShahRobert C WangBarry KapikThomas A Ciulla
Published in: The British journal of ophthalmology (2021)
Approximately 50% of patients did not require additional treatment for up to 9 months following the last CLS-TA administration.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • prognostic factors
  • systemic lupus erythematosus
  • patient reported outcomes
  • ankylosing spondylitis
  • patient reported